Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda’s Pentarin® miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells. The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor. Tarveda’s first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (“HSP90”) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment, but which remains relatively dormant in normal tissue. Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors. PEN-866 is a miniature drug conjugate that selectively binds to the activated form of HSP90 linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 has commenced its Phase 2a trial in various types of solid tumors. In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors.
View Top Employees from Tarveda TherapeuticsWebsite | https://www.tarvedatx.com/ |
Revenue | $10 million |
Funding | $94 million |
Employees | 13 (13 on RocketReach) |
Founded | 2011 |
Address | 134 Coolidge Avenue, Watertown, Massachusetts 02472, US |
Phone | (617) 923-4100 |
Fax | (617) 923-4101 |
Technologies |
JavaScript,
HTML,
Twitter
+9 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Health Care, Business Services, Health Diagnostics, Medical, Therapeutics |
Competitors | Angiochem, Biokine Therapeutics Ltd., Step Pharma, Turning Point Therapeutics, Visterra Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies |
Looking for a particular Tarveda Therapeutics employee's phone or email?
The Tarveda Therapeutics annual revenue was $10 million in 2024.
Laura Mei is the Senior Vice President, Clinical Operations of Tarveda Therapeutics.
13 people are employed at Tarveda Therapeutics.
Tarveda Therapeutics is based in Watertown, Massachusetts.
The NAICS codes for Tarveda Therapeutics are [541714, 5417, 541, 54, 54171].
The SIC codes for Tarveda Therapeutics are [873, 87].